Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial.
Camus V, Belot A, Oberic L, Sibon D, Ghesquières H, Thieblemont C, Fruchart C, Casasnovas O, Michot JM, Molina TJ, Bosly A, Joubert C, Haioun C, Nicolas-Virelizier E, Feugier P, Fitoussi O, Delarue R, Tilly H. Camus V, et al. Among authors: nicolas virelizier e. Blood Adv. 2022 Dec 27;6(24):6169-6179. doi: 10.1182/bloodadvances.2022007609. Blood Adv. 2022. PMID: 35737565 Free PMC article.
Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Nicolas-Virelizier E, Ségura-Ferlay C, Ghesquières H, Chassagne-Clément C, Gargi T, Biron P, Belhabri A, Rey P, Faurie P, Chabaud S, Sebban C. Nicolas-Virelizier E, et al. Hematol Oncol. 2015 Mar;33(1):1-8. doi: 10.1002/hon.2130. Epub 2014 Feb 5. Hematol Oncol. 2015. PMID: 24496668
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
Maurer MJ, Ghesquières H, Jais JP, Witzig TE, Haioun C, Thompson CA, Delarue R, Micallef IN, Peyrade F, Macon WR, Jo Molina T, Ketterer N, Syrbu SI, Fitoussi O, Kurtin PJ, Allmer C, Nicolas-Virelizier E, Slager SL, Habermann TM, Link BK, Salles G, Tilly H, Cerhan JR. Maurer MJ, et al. J Clin Oncol. 2014 Apr 1;32(10):1066-73. doi: 10.1200/JCO.2013.51.5866. Epub 2014 Feb 18. J Clin Oncol. 2014. PMID: 24550425 Free PMC article. Clinical Trial.
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.
Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P; Lymphoma Study Association (LYSA). Mounier N, et al. Ann Oncol. 2014 Aug;25(8):1622-8. doi: 10.1093/annonc/mdu189. Epub 2014 May 14. Ann Oncol. 2014. PMID: 24827123 Free article. Clinical Trial.
Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.
Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, Chassagne-Clément C, Inwards DJ, Gargi T, Johnston PB, Nicolas-Virelizier E, Macon WR, Peix M, Micallef IN, Sebban C, Nowakowski GS, Porrata LF, Weiner GJ, Witzig TE, Habermann TM, Link BK. Thompson CA, et al. J Clin Oncol. 2014 Nov 1;32(31):3506-12. doi: 10.1200/JCO.2014.55.7561. Epub 2014 Sep 29. J Clin Oncol. 2014. PMID: 25267745 Free PMC article.
Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.
Lazarovici J, Dartigues P, Brice P, Obéric L, Gaillard I, Hunault-Berger M, Broussais-Guillaumot F, Gyan E, Bologna S, Nicolas-Virelizier E, Touati M, Casasnovas O, Delarue R, Orsini-Piocelle F, Stamatoullas A, Gabarre J, Fornecker LM, Gastinne T, Peyrade F, Roland V, Bachy E, André M, Mounier N, Fermé C. Lazarovici J, et al. Haematologica. 2015 Dec;100(12):1579-86. doi: 10.3324/haematol.2015.133025. Epub 2015 Oct 1. Haematologica. 2015. PMID: 26430172 Free PMC article.
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.
Dupuis J, Morschhauser F, Ghesquières H, Tilly H, Casasnovas O, Thieblemont C, Ribrag V, Bossard C, Le Bras F, Bachy E, Hivert B, Nicolas-Virelizier E, Jardin F, Bastie JN, Amorim S, Lazarovici J, Martin A, Coiffier B. Dupuis J, et al. Lancet Haematol. 2015 Apr;2(4):e160-5. doi: 10.1016/S2352-3026(15)00023-X. Epub 2015 Mar 17. Lancet Haematol. 2015. PMID: 26687958 Clinical Trial.
Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
Houillier C, Ghesquières H, Chabrot C, Soussain C, Ahle G, Choquet S, Nicolas-Virelizier E, Bay JO, Vargaftig J, Gaultier C, Touitou V, Martin-Duverneuil N, Cassoux N, Le Garff-Tavernier M, Costopoulos M, Faurie P, Hoang-Xuan K. Houillier C, et al. J Neurooncol. 2017 Jun;133(2):315-320. doi: 10.1007/s11060-017-2435-7. Epub 2017 Apr 21. J Neurooncol. 2017. PMID: 28432587
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.
Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O; LYSA Group. Le Gouill S, et al. N Engl J Med. 2017 Sep 28;377(13):1250-1260. doi: 10.1056/NEJMoa1701769. N Engl J Med. 2017. PMID: 28953447 Free article. Clinical Trial.
70 results